Department of Medicine

(FEBRUARY 28, 2023) James Gerson, M.D., assistant professor of medicine and director of the CAR T-Cell Program, spoke to the Press-Republican about the promising cancer treatment called CAR T-cell therapy that is now available at the UVM Cancer Center.

The University of Vermont’s Larner College of Medicine features some of the world’s foremost cardiovascular researchers, experts in cardiovascular disease risk factors, thrombosis, atherosclerosis, stroke, and heart failure. the science shared by early-career investigators at the Cardiovascular Research Institute of Vermont’s fourth annual Viridis Montis Challenge, it was apparent that the institution’s reputation and legacy in the field of cardiovascular research will continue to have a global impact.

The University of Vermont Cancer Center now offers a novel, highly effective form of cancer treatment called CAR T-cell therapy, and recently began treating patients. The Cancer Center is the only health care institution in Vermont and northern New York to provide the treatment.

A new study published in JAMA Cardiology by UVM cardiovascular medicine fellow Margaret Infeld, M.D., M.S., and colleagues found evidence that by implementing a tailored acceleration of heart rates, they could reduce congestion and improve the circulation of blood in heart failure patients with "stiff" hearts.

Randall F. Holcombe, M.D., M.B.A., director of the UVM Cancer Center and chief of the Division of Hematology and Oncology in the Department of Medicine, has been appointed as associate dean for cancer programs at the UVM Larner College of Medicine.